Darp101 (@DarpResearch) profile picture

Stock investor, inventor and rusty geologist.

Joined June 2022
Photo by Darp101 (@DarpResearch)Photo by Darp101 (@DarpResearch)Photo by Darp101 (@DarpResearch)Photo by Darp101 (@DarpResearch)Photo by Darp101 (@DarpResearch)Photo by Darp101 (@DarpResearch)Photo by Darp101 (@DarpResearch)Photo by Darp101 (@DarpResearch)Photo by Darp101 (@DarpResearch)Photo by Darp101 (@DarpResearch)
RT @rwelsh63: What a terrific write-up on NervGen Pharma’s NVG-291. Clear, informative, and well-sourced — it explains how it works and cit…
1
61
Replying to @DarpResearch
I know the results incredible! tiktok.com/t/ZT675WuNo/
2
2
7
505
BOUGHT MORE! Beacon is now my biggest position. I expect Beacon Minerals $BCN.AX to double soon. Here is why: Beacon has received the first batch of 2,970 assay results from multiple mineralised zones. Significant high-grade intersections include:  5 metres @ 39.3 g/t gold from 49 metres (IGGC_210) Including 1 metre @ 179.0 g/t gold from 49 metres  6 metres @ 46.8 g/t gold from 32 metres (IGGC_219) Including 2 metres @ 135.5 g/t gold from 32 metres  2 metres @ 39.9 g/t gold from 41 metres (IGGC_232) Including 1 metre @ 75.9 g/t gold from 41 metres  2 metres @ 21.9 g/t gold from 18 metres (IGGC_210)  8 metres @ 4.34 g/t gold from 33 metres (IGGC_234) Including 1 metre @ 22.6 g/t gold from 35 metres  7 metres @ 3.6 g/t gold from 47 metres (IGGC_248) Including 3 metres @ 5.4 g/t gold from 47 metres  Beacon is expecting the remaining 13,536 assay results to be received over the next 6 to 8 weeks. My other biggest positions are: $JAG.TO $MMY.V.
2
5
1
14
3,048
Replying to @FDA
@US_FDA @FDA_Drug_Info @FDA On behalf of all the SCI sufferers, pls approve it and bring it to the markets ASAP. You will save the economy by billions of USD which are consumed in the insurance bills. Pls let it work #NVG291 $NGENF
4
7
1
13
1,327
Darp101 retweeted
Nervgen CEO Mike Kelly & CFO Bill Adams made a presentation on June 27th at the SCI conference to discuss early results of the P2 trial in patients with chronic SCI, met with interested parties afterwards. Replay at nervgen.com/presentations/
I can not vouch if this fellow really met with NervGen, but this is on StockTwits: rwelsh633Jun 27, 2025 2:30 PM $NGENF I met with Mike Kelly & Bill Adams. They are still working through a lot of the data and haven’t decided how to release it yet if that will be an event or through a press release, but they’re being very very cautious as they’re preparing to meet with the FDA in Q3 or Q4. They want to make sure that their upcoming meeting with the FDA is successful by all means. That’s why they haven’t marketed the results. They don’t want the FDA to see them as trying to pump their stock, sounded like they are planning for the phase 3 trial, Patient study in several centers in the US and Canada didn’t sound like they were going to expand the study criteria at all because when you start expanding the criteria than your results could be unfavorable. In order to do the study, they’re gonna need $75 million. They’ve met with a few institutions but biotech institutions are pretty slow so he said we’ll see how funding comes about as far as adding other diseases in the pipeline. stocktwits.com/rwelsh633/mes… It all has to do with money if they had the money they would had MS, heart damage ALS, But as they show this works in spinal cord injury, the money will start coming in. Expanded access will take some time for the patients to get back on the drug because each physician has to set up the study in it. All depends on the physician monitoring the patient, so it could take some time and the patients that were on placebo for them to start taking the drug. They have to do some work with the FDA and that’s also gonna take a little more time. My last question was as an investor what would you recommend and Mike said keep investing … double down! OK this would explain why they are not promoting it, if true. I dissagree, the money would be so much easier to get and on better terms if they publicized the good results.
1
2
5
372
From an amazing Michael Crichton talk: “Media carries with it a credibility that is totally undeserved. You have all experienced this, in what I call the Murray Gell-Mann Amnesia effect. (I refer to it by this name because I once discussed it with Murray Gell-Mann, and by dropping a famous name I imply greater importance to myself, and to the effect, than it would otherwise have.) Briefly stated, the Gell-Mann Amnesia effect is as follows. You open the newspaper to an article on some subject you know well. In Murray's case, physics. In mine, show business. You read the article and see the journalist has absolutely no understanding of either the facts or the issues. Often, the article is so wrong it actually presents the story backward—reversing cause and effect. I call these the "wet streets cause rain" stories. Paper's full of them. In any case, you read with exasperation or amusement the multiple errors in a story, and then turn the page to national or international affairs, and read as if the rest of the newspaper was somehow more accurate about Palestine than the baloney you just read. You turn the page, and forget what you know. That is the Gell-Mann Amnesia effect. I'd point out it does not operate in other arenas of life. In ordinary life, if somebody consistently exaggerates or lies to you, you soon discount everything they say. In court, there is the legal doctrine of falsus in uno, falsus in omnibus, which means untruthful in one part, untruthful in all. But when it comes to the media, we believe against evidence that it is probably worth our time to read other parts of the paper.”
6,764
19,675
1,763
91,337
19,276,792
It's a mystery to me why the energy sector remains so hated and ignored. No other sector remotely comes close to comparing: lowest debt + highest profitability, combined with highest free cashflow and months away from 75%-100% return of capital inflection.
102
134
14
875
151,901